Hidradenitis Suppurativa
Conditions
Brief summary
The trial enrolls patients with moderate to severe Hidradenitis Suppurativa (HS). The primary goal of the trial is to evaluate the safety and tolerability of IFX-1 administered over 8 weeks in these patients. In addition the trial aims to characterize the pharmacokinetics and pharmacodynamics of IFX-1 as well as to generate preliminary data on the efficacy of IFX-1 on clinical endpoints (e.g., Hidradenitis Suppurativa Clinical Response (HiSCR), Dermatology Life Quality Index (DLQI), Visual Analog Scale (VAS) for disease, VAS for pain, Hidradenitis Suppurativa - Physician's Global Assessment (HS-PGA), Modified Sartorius Score (mSS)).
Interventions
BIOLOGICALIFX-1
chimeric, monoclonal antibody
Sponsors
InflaRx GmbH
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female patients ≥ 18 years old 2. Written informed consent 3. Diagnosis of HS for at least 1 year 4. Hidradenitis suppurativa (HS) lesions in at least 2 distinct anatomic areas, one of which is Hurley Stage II or III 5. Total AN (abscesses and nodules) count ≥3 6. Patients with either primary or secondary failure of biological treatment or are not eligible for treatment with other biologicals 7. Failure of previous antimicrobial treatments
Exclusion criteria
1. Body weight above 150 kg or body weight below 60 kg 2. Has a draining fistula count of greater than 30 at baseline 3. Surgical management planned within the next 24 weeks 4. Occurrence of a flare-up of HS leading to intravenous antimicrobial treatment within the last 14 days 5. Any other disease and condition that is likely to interfere with evaluation of study product, outcome assessment or satisfactory conduct of the study 1. Active infection 2. Severe congestive heart failure (i.e., New York Heart Association (NYHA) Class IV) 3. Depression 4. History of systemic lupus erythematosus or rheumatoid arthritis 5. Any immunodeficiency disease 6. Active hematological or solid malignant tumor 7. Patients must not have had any other active skin disease or condition (e.g., bacterial, fungal, or viral infection) that may have interfered with assessment of HS. 6. One of the following abnormal laboratory results 1. White blood cell count \< 2,500/mm3 2. Neutrophil count \< 1000/mm3 3. Serum Creatinine \> 3 x Upper Normal Limit (UNL) 4. Total Bilirubin \> 2 x UNL 5. Alanine-Aminotransferase (ALAT) \> 2 x UNL 6. Positive screening test for Hepatitis B, Hepatitis C, or HIV 1/2 7. Prior administration of any biological compound in the last 3 months 8. Intake of corticosteroids defined as daily intake of prednisone or equivalent more than 1 mg/kg for the last three weeks; 9. Intake of Immunosuppressive drugs within past 30 days (e.g., cyclosporine, tacrolimus) 10. General
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients with at least possibly related treatment-emergent adverse events (TEAEs) | up to Day 134 |
| Number of patients with detection of anti-drug antibodies (pre-/post-dosing) | up to Day 134 |
Secondary
| Measure | Time frame |
|---|---|
| Percentage change from baseline in total abscess and nodule (AN) count per time point | Data will be collected at the following time points: Day 1, 22, 29, 36, 43, 50, 78, 106 and Day 134 |
| Hidradenitis Suppurativa Clinical Response (HiSCR) per time point | Data will be collected at the following time points: Day 1, 22, 29, 36, 43, 50, 78, 106 and Day 134 |
| Achievement of Hidradenitis Suppurativa - Physician's Global Assessment (HS-PGA) of clear, minimal, or mild among patients with at least 2 grades improvement (reduction) from baseline | Data will be collected at the following time points: Day 1, Day 22, Day 50 and Day 134 |
| HS-PGA score per time point | Data will be collected at the following time points: Day 1, 22, 29, 36, 43, 50, 78, 106 and Day 134 |
| Achievement of at least a 30% reduction and at least a 10 mm reduction in the Visual Analog Scale (VAS) for pain, among patients who had a baseline pain assessment ≥ 30 mm | At each visit from Day 1 until Day 134 |
| Plasma concentration of IFX-1 | From Day 1 until Day 134 |
| Change from baseline in VAS pain score per time point | At each visit from Day 1 until Day 134 |
| VAS disease score per time | At each visit from Day 1 until Day 134 |
| Change from baseline in VAS disease score per time point | At each visit from Day 1 until Day 134 |
| Dermatology Life Quality Index (DLQI) per time point | Data will be collected at the following time points: Day 1, Day 22, Day 50 and Day 134 |
| Change from baseline in DLQI per time point | Data will be collected at the following time points: Day 1, Day 22, Day 50 and Day 134 |
| VAS pain score per time point | At each visit from Day 1 until Day 134 |
| Plasma concentration of C5a | Data will be collected at the following time points: Day 1, Day 22, Day 50 and Day 134 |
Countries
Greece
Outcome results
None listed